Nkarta (NKTX) Stock Price
Nkarta Price
Revenue at Nkarta has contracted by 99.2% per year over the past 2 years to 385.00 USD. Nkarta's net margin stands at -23,730,130.0%, down from -4.2% several years earlier. Analysts set a median price target of 9.00 USD, implying 296.5% above the current price. Of 13 analysts, 12 rate the stock a buy — an overall Buy consensus.
Nkarta stock price
Nkarta business model & stock analysis
Frequently asked questions about Nkarta
Nkarta Inc is a biotechnology company specializing in the development of cell therapies to treat cancer. The company's business model revolves around advancing its proprietary natural killer (NK) cell therapies. Nkarta Inc focuses on developing and commercializing off-the-shelf treatments that harness the power of the body's immune system to eliminate tumors. By genetically engineering and enhancing NK cells to target and kill cancer cells, Nkarta Inc aims to provide effective and accessible treatments for patients. As a leading player in the field of cell therapy, Nkarta Inc is committed to revolutionizing cancer treatment through its innovative business model.
Nkarta Inc is primarily active in the biotechnology industry.
The main competitors of Nkarta Inc in the market are Adaptimmune Therapeutics, bluebird bio, and Celgene Corporation.
Nkarta Inc, a biotechnology company founded in 2015, focuses on developing cellular therapies for cancer treatment. With headquarters in South San Francisco, California, Nkarta operates with a vision to harness the power of the body's immune system to combat cancer effectively. The company specializes in natural killer (NK) cells, which play a crucial role in protecting against tumor growth. Leveraging their proprietary technology, Nkarta engineers enhanced NK cells, known as NKT cells, to enhance their potency and persistence. As a prominent player in the field of cellular immunotherapy, Nkarta Inc strives to advance innovative treatments and improve outcomes for patients battling various cancers.
Nkarta Inc, a leading biotechnology company, has achieved several significant milestones. Firstly, they successfully completed their IPO in 2020, raising substantial capital to fund their ongoing research and development efforts. Additionally, Nkarta has made remarkable progress in advancing their pipeline of novel natural killer (NK) cell therapies. They have received clearance from the FDA for their Investigational New Drug (IND) application, allowing them to initiate clinical trials. Nkarta has also forged strategic collaborations with renowned institutions, further reinforcing their expertise and expanding their reach in the field of cell therapies. These milestones demonstrate Nkarta Inc's commitment to revolutionizing cancer treatment through innovative therapies harnessing the power of NK cells.
Nkarta Inc is primarily present in the United States.
Nkarta Inc represents a strong set of values and corporate philosophy. As a biotechnology company, Nkarta Inc is committed to transforming the lives of patients with complex diseases by harnessing the power of natural killer (NK) cells. The company believes in scientific innovation and collaboration to develop groundbreaking therapies. Nkarta Inc is devoted to delivering effective and safe treatments while maintaining the highest ethical standards. With a passion for improving patient outcomes, Nkarta Inc strives to be a leader in the biotech industry by driving advancements in cell therapy.
Analysts currently set an average price target of 9.00 USD for the Nkarta stock (median: 9.00 USD), implying +296.5 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the Nkarta stock: 12 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Nkarta to generate revenue of 2.25 M USD and earnings per share of -1.60 USD.
Converted at the current exchange rate, the Nkarta share trades at 2.03 EUR (2.27 USD).
The Nkarta share (NKTX) is listed on 1 stock exchanges, including: NASDAQ (NKTX).
Nkarta Inc is a biotechnology company specializing in developing innovative and personalized therapies for cancer patients based on natural killer cells (NK cells). The company has a business model that spans multiple sectors and offers a wide range of products and services. The first sector of Nkarta is the research and development of personalized NK cell therapies for cancer patients. NK cells are part of the innate immune system and can directly attack and kill cancer cells. Nkarta utilizes advanced technologies such as CRISPR/Cas9 genome editing and CAR (chimeric antigen receptor)-based NK cell therapies to enhance the effectiveness of NK cells. The company is working on developing therapies for various types of cancer, including leukemia, lymphoma, and solid tumors. The second sector of Nkarta is the manufacturing and provision of NK cell products for clinical studies. Nkarta has its own production facility that is GMP certified and meets the highest quality standards. The company offers customers a wide range of products such as natural killer cells (NK cells) obtained from the patient's blood or donor blood, CAR NK cells, as well as specialized devices and consumables. The third sector of Nkarta is collaboration with other companies and institutions in the development of personalized NK cell therapies. Nkarta works with various partners to accelerate the development of NK cell therapies and improve the effectiveness of NK cells in cancer therapy. The company recently partnered with CRISPR Therapeutics to further develop its CAR NK cell technology and conduct clinical studies. In addition to these sectors, Nkarta is also active in the field of financing. The company has conducted several funding rounds, raising over $100 million. These funds are used to finance research and development, manufacturing of NK cell products, and expansion of business operations. In summary, Nkarta offers a wide range of products and services in the field of personalized NK cell therapy. The company has a comprehensive business model that spans multiple sectors, including research and development, manufacturing of NK cell products, collaboration with partners, and financing. Thanks to its innovative technologies and highly skilled employees, Nkarta is well-positioned to offer its customers effective and personalized cancer treatment.
The expected revenue of Nkarta is 2.25 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Nkarta is -118.50 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Nkarta is currently -1.42. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Nkarta stock.
The price-to-sales ratio (P/S) of Nkarta is currently 74.70. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Nkarta stock.
The Eulerpool Quality Score for Nkarta is 2/10.
The ISIN of Nkarta is US65487U1088. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Nkarta is A2P797. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Nkarta is NKTX. The ticker symbol is used to trade Nkarta shares on the stock exchange.
Nkarta stock
Nkarta Ticker
Nkarta FIGI
All fundamentals and in-depth analysis of Nkarta
Our stock analysis for Nkarta stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nkarta. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.